Zacks Investment Research downgraded shares of OpGen (NASDAQ:OPGN) from a buy rating to a hold rating in a report issued on Tuesday.
According to Zacks, “OpGen, Inc. is a microbial genetics analysis company. The Company offers optical mapping services for analysis of microbial, yeast and fungal genomic architecture. OpGen, Inc. headquartered in Gaithersburg, Maryland. “
OPGN has been the subject of a number of other reports. ValuEngine lowered OpGen from a sell rating to a strong sell rating in a research note on Thursday, January 25th. HC Wainwright increased their price target on OpGen to $9.00 and gave the company a buy rating in a research note on Wednesday, February 7th.
OpGen (OPGN) opened at $2.40 on Tuesday. OpGen has a one year low of $1.78 and a one year high of $31.25. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.23 and a quick ratio of 1.13.
An institutional investor recently raised its position in OpGen stock. Vanguard Group Inc. boosted its position in shares of OpGen Inc (NASDAQ:OPGN) by 1.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 342,860 shares of the medical research company’s stock after buying an additional 5,500 shares during the period. Vanguard Group Inc. owned approximately 1.25% of OpGen worth $219,000 as of its most recent SEC filing.
ILLEGAL ACTIVITY WARNING: “OpGen (OPGN) Stock Rating Lowered by Zacks Investment Research” was first posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.thelincolnianonline.com/2018/03/14/opgen-opgn-stock-rating-lowered-by-zacks-investment-research.html.
OpGen Company Profile
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.